Skip to content
Research

Menopause Hormone Therapy and GLP-1 Weight Loss: What a New Mayo Clinic Study Found

4 min readBy Jeremy H., GLP-1 Nutrition Researcher
Menopause Hormone Therapy and GLP-1 Weight Loss: What a New Mayo Clinic Study Found

A Mayo Clinic Florida analysis presented at The Menopause Society's 2026 Annual Meeting found that midlife women using menopause hormone therapy lost more weight on semaglutide than women who were not using hormone therapy. The study has not yet been peer reviewed. It was a conference presentation of a retrospective look at real-world records, not a randomized trial, so it shows an association, not proof that hormone therapy causes extra weight loss.

What the Study Found

The analysis covered about 3,900 women over age 45 with a body mass index above 27 who were treated for overweight or obesity: nearly 2,400 taking semaglutide (the active ingredient in Ozempic and Wegovy) and nearly 1,500 taking tirzepatide (the active ingredient in Mounjaro and Zepbound). The researchers compared women using menopause hormone therapy with women who were not.

  • Semaglutide: Women using hormone therapy had significantly greater and more sustained weight loss than women not using it.
  • Tirzepatide: Women using hormone therapy lost more weight early on, but by the end of the study period the difference was no longer statistically significant.

The released materials do not include exact weight-loss percentages, confidence intervals, or follow-up times, so this article does not report any. The lead author is Dr. Regina Castaneda, a postdoctoral research fellow in women's health at Mayo Clinic Florida. The presentation, titled "Menopause Hormone Therapy and Weight Loss Response to GLP-1-Based Therapies in Midlife Women: A Retrospective Cohort Study," was given at the meeting in San Diego, October 20–24, 2026 (The Menopause Society press release, October 20, 2026).

What the Finding Does and Does Not Mean

This was a retrospective observational cohort study. The women were not randomly assigned to hormone therapy, so differences between the groups — in health, other medicines, or care — could explain part of the result. The authors say the same thing. Castaneda described the results as hypothesis-generating and said they need confirmation in adequately designed prospective trials. She also stated plainly that weight loss is not an indication for menopause hormone therapy.

That last point matters. Menopause hormone therapy has specific clinical indications, such as bothersome menopause symptoms, and weight management is not one of them. The study is not a reason to start, stop, or change hormone therapy for weight loss. Anyone considering a change to hormone therapy or a GLP-1 medication should talk with their own clinician, who knows their history, risks, and treatment goals.

The researchers also noted that the stronger signal with semaglutide than with tirzepatide deserves further study and may point to an interaction specific to GLP-1 signaling, based on preclinical data suggesting a possible synergistic effect between estrogen and GLP-1 signaling. That is a hypothesis for future research, not an established mechanism.

GLP-1 medication news, in plain English

New approvals, pens, pills, prices and label changes across GLP-1 medications. One free email a week.

Why This Study Drew Attention

About one in five women aged 50 to 64 report current or past use of a GLP-1-based obesity medication, the highest of any age group in the United States, according to The Menopause Society. Weight gain during midlife is a common concern, and earlier, smaller studies had already pointed in the same direction. A 2024 Mayo Clinic record review of 106 postmenopausal women on semaglutide found the hormone-therapy group lost more weight, but with only 16 women in the hormone-therapy group it could show only an association. The new analysis is the first known large real-world cohort on the question, and it found the same signal in a larger, independent group.

See our GLP-1 and menopause guide for the broader evidence on GLP-1 medications, hormone therapy, muscle, and bone health during menopause.

Bottom Line

In about 3,900 midlife women, menopause hormone therapy was linked to greater and more sustained weight loss on semaglutide, while the final difference on tirzepatide was not statistically significant. The study is a conference presentation of retrospective data, has not yet been peer reviewed, and reports no exact weight-loss figures. It adds to an existing signal but does not change what hormone therapy is for, and it is not a basis for starting, stopping, or changing hormone therapy to improve weight loss.

This article is for education and does not replace medical advice. Medication and hormone-therapy decisions should be made with a qualified clinician who knows your history.


Sources: The Menopause Society press release, October 20, 2026; presentation at The Menopause Society 2026 Annual Meeting, San Diego, October 20–24, 2026. Figures checked November 2026.

GLP-1 medication news, in plain English

New approvals, pens, pills, prices and label changes across GLP-1 medications. One free email a week.

We respect your privacy. Unsubscribe anytime.

Next up

A few related reads to keep your momentum.

Related articles

Written by
J
Jeremy H.
GLP-1 Nutrition Researcher

Nutrition researcher and founder of The GLPSpot. Jeremy built this site after watching friends and family struggle with the nutritional challenges of reduced appetite on GLP-1 medications — loss of muscle mass, dehydration, and nutrient deficiencies.

Published:
Medical Disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment.